These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 15137034)

  • 21. An in vitro screening assay based on synthetic prion protein peptides for identification of fibril-interfering compounds.
    Boshuizen RS; Langeveld JP; Salmona M; Williams A; Meloen RH; Langedijk JP
    Anal Biochem; 2004 Oct; 333(2):372-80. PubMed ID: 15450815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The dimeric and tetrameric octarepeat fragments of prion protein behave differently to its monomeric unit.
    Valensin D; Luczkowski M; Mancini FM; Legowska A; Gaggelli E; Valensin G; Rolka K; Kozlowski H
    Dalton Trans; 2004 May; (9):1284-93. PubMed ID: 15252619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Copper-dependent degradation of recombinant ovine prion protein. Phosphatidylinositol stimulates aggregation and copper-driven disappearance of prion protein.
    Tsiroulnikov K; Chobert JM; Haertlé T
    FEBS J; 2006 May; 273(9):1959-65. PubMed ID: 16640559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generation of genuine prion infectivity by serial PMCA.
    Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
    Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydrogen peroxide cleavage of the prion protein generates a fragment able to initiate polymerisation of full length prion protein.
    Abdelraheim SR; Královicová S; Brown DR
    Int J Biochem Cell Biol; 2006; 38(8):1429-40. PubMed ID: 16595185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel biomimetic affinity ligands for human tissue plasminogen activator.
    Wu F; Yu J; Li R
    Biochem Biophys Res Commun; 2007 Apr; 355(3):673-8. PubMed ID: 17307143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prion strain discrimination using luminescent conjugated polymers.
    Sigurdson CJ; Nilsson KP; Hornemann S; Manco G; Polymenidou M; Schwarz P; Leclerc M; Hammarström P; Wüthrich K; Aguzzi A
    Nat Methods; 2007 Dec; 4(12):1023-30. PubMed ID: 18026110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The physical basis of how prion conformations determine strain phenotypes.
    Tanaka M; Collins SR; Toyama BH; Weissman JS
    Nature; 2006 Aug; 442(7102):585-9. PubMed ID: 16810177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Copper brain homeostasis: role of amyloid precursor protein and prion protein.
    Inestrosa NC; Cerpa W; Varela-Nallar L
    IUBMB Life; 2005 Sep; 57(9):645-50. PubMed ID: 16203684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamics of yeast prion aggregates in single living cells.
    Kawai-Noma S; Ayano S; Pack CG; Kinjo M; Yoshida M; Yasuda K; Taguchi H
    Genes Cells; 2006 Sep; 11(9):1085-96. PubMed ID: 16923127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydrogen/deuterium exchange mass spectrometry identifies two highly protected regions in recombinant full-length prion protein amyloid fibrils.
    Nazabal A; Hornemann S; Aguzzi A; Zenobi R
    J Mass Spectrom; 2009 Jun; 44(6):965-77. PubMed ID: 19283723
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prion species barrier between the closely related yeast proteins is detected despite coaggregation.
    Chen B; Newnam GP; Chernoff YO
    Proc Natl Acad Sci U S A; 2007 Feb; 104(8):2791-6. PubMed ID: 17296932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural insights into alternate aggregated prion protein forms.
    Polano M; Bek A; Benetti F; Lazzarino M; Legname G
    J Mol Biol; 2009 Nov; 393(5):1033-42. PubMed ID: 19720066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prion and water: tight and dynamical hydration sites have a key role in structural stability.
    De Simone A; Dodson GG; Verma CS; Zagari A; Fraternali F
    Proc Natl Acad Sci U S A; 2005 May; 102(21):7535-40. PubMed ID: 15894615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new method for the screening of solid-phase combinatorial libraries for affinity chromatography.
    Roque AC; Taipa MA; Lowe CR
    J Mol Recognit; 2004; 17(3):262-7. PubMed ID: 15137035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expansion of the octarepeat domain alters the misfolding pathway but not the folding pathway of the prion protein.
    Leliveld SR; Stitz L; Korth C
    Biochemistry; 2008 Jun; 47(23):6267-78. PubMed ID: 18473442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis of monomeric and dimeric acridine compounds as potential therapeutics in Alzheimer and prion diseases.
    Csuk R; Barthel A; Raschke C; Kluge R; Ströhl D; Trieschmann L; Böhm G
    Arch Pharm (Weinheim); 2009 Dec; 342(12):699-709. PubMed ID: 19899100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring the essential collective dynamics of interacting proteins: application to prion protein dimers.
    Issack BB; Berjanskii M; Wishart DS; Stepanova M
    Proteins; 2012 Jul; 80(7):1847-65. PubMed ID: 22488640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein assembly directed by synthetic molecular recognition motifs.
    Ma M; Bong D
    Org Biomol Chem; 2011 Nov; 9(21):7296-9. PubMed ID: 21912803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-activity relationship refinement and further assessment of indole-3-glyoxylamides as a lead series against prion disease.
    Thompson MJ; Louth JC; Ferrara S; Sorrell FJ; Irving BJ; Cochrane EJ; Meijer AJ; Chen B
    ChemMedChem; 2011 Jan; 6(1):115-30. PubMed ID: 21154498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.